A narcotic analgesic morphinan used as a sedative in veterinary practice. In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes. Etorphine is only available to the patients under an official prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Hydrocodone | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Magnesium sulfate | The therapeutic efficacy of Etorphine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Etorphine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Orphenadrine | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Pramipexole | Etorphine may increase the sedative activities of Pramipexole. |
| Ropinirole | Etorphine may increase the sedative activities of Ropinirole. |
| Rotigotine | Etorphine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Etorphine. |
| Sodium oxybate | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Thalidomide | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Etorphine is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Etorphine is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Etorphine. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Etorphine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etorphine. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Etorphine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Etorphine. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etorphine. |
| Naltrexone | The therapeutic efficacy of Etorphine can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Etorphine. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Etorphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Etorphine. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Etorphine. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etorphine. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Etorphine. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Etorphine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Etorphine. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diamorphine is combined with Etorphine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Bezitramide is combined with Etorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Etorphine is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Etorphine is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Etorphine is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Etorphine is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Etorphine is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Etorphine is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Etorphine is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Etorphine is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Etorphine is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Etorphine is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Etorphine is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Etorphine can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Etorphine is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Etorphine is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Etorphine is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Etorphine is combined with Carfentanil, C-11. |
| Naloxegol | The risk or severity of adverse effects can be increased when Etorphine is combined with Naloxegol. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Etorphine is combined with Benzhydrocodone. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Etorphine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Etorphine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Etorphine. |
| Mirtazapine | Etorphine may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Etorphine. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Alaproclate. |
| Ethanol | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Etorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Etorphine. |
| Phentermine | Phentermine may increase the analgesic activities of Etorphine. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Etorphine. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Etorphine. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Etorphine. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Etorphine. |
| MMDA | MMDA may increase the analgesic activities of Etorphine. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Etorphine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Etorphine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Etorphine. |